ATE393152T1 - Phtalazine derivate mit angiogenesis inhibierender wirkung - Google Patents

Phtalazine derivate mit angiogenesis inhibierender wirkung

Info

Publication number
ATE393152T1
ATE393152T1 AT02738031T AT02738031T ATE393152T1 AT E393152 T1 ATE393152 T1 AT E393152T1 AT 02738031 T AT02738031 T AT 02738031T AT 02738031 T AT02738031 T AT 02738031T AT E393152 T1 ATE393152 T1 AT E393152T1
Authority
AT
Austria
Prior art keywords
treatment
derivatives
phtalazine
inhibiting effect
angiogenesis inhibiting
Prior art date
Application number
AT02738031T
Other languages
English (en)
Inventor
Guido Bold
Paul Manley
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE393152T1 publication Critical patent/ATE393152T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02738031T 2001-05-04 2002-05-03 Phtalazine derivate mit angiogenesis inhibierender wirkung ATE393152T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0111078.2A GB0111078D0 (en) 2001-05-04 2001-05-04 Organic compounds

Publications (1)

Publication Number Publication Date
ATE393152T1 true ATE393152T1 (de) 2008-05-15

Family

ID=9914117

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02738031T ATE393152T1 (de) 2001-05-04 2002-05-03 Phtalazine derivate mit angiogenesis inhibierender wirkung

Country Status (12)

Country Link
US (3) US7399761B2 (de)
EP (1) EP1387836B1 (de)
JP (1) JP4365586B2 (de)
CN (1) CN1314681C (de)
AT (1) ATE393152T1 (de)
BR (1) BR0209332A (de)
CA (1) CA2446051A1 (de)
DE (1) DE60226225T2 (de)
ES (1) ES2301648T3 (de)
GB (1) GB0111078D0 (de)
PT (1) PT1387836E (de)
WO (1) WO2002090346A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712234B1 (de) * 2001-09-12 2009-01-28 Novartis AG Die Verwendung von 4-Pyridylmethylphthalazinen zur Behandlung von Nierentumoren
WO2004002485A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor
EP1738752A1 (de) * 2002-12-27 2007-01-03 Schering Aktiengesellschaft Pharmazeutische Zusammensetzungen enthaltend cis-Retine Säure
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1919906B1 (de) * 2005-08-29 2011-10-12 Vertex Pharmaceuticals Incorporated 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin-kinasen nützlich sind
RU2522444C2 (ru) 2008-08-27 2014-07-10 Лео Фарма А/С Производные пиридина в качестве ингибиторов рецепторов фактора роста эндотелия сосудов 2 подтипа (vegfr-2) и протеинтирозинкиназы
JP6088063B2 (ja) * 2012-11-16 2017-03-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
JP6282721B2 (ja) 2013-03-14 2018-02-21 ダート・ニューロサイエンス・（ケイマン）・リミテッド Ｐｄｅ４阻害剤としての置換ピリジン及びピラジン化合物
JP2024505256A (ja) * 2021-01-28 2024-02-05 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 神経変性、変性及び代謝性障害の処置のための化合物並びにその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567431A (de) 1957-05-07
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US4665181A (en) * 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
JPH03106875A (ja) 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
DE69533057T2 (de) 1994-08-09 2005-06-16 Eisai Co., Ltd. Kondensierte pyridazinverbindungen
MY117098A (en) 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CN1660840A (zh) * 1999-03-30 2005-08-31 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
AR025068A1 (es) 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis

Also Published As

Publication number Publication date
US8034814B2 (en) 2011-10-11
GB0111078D0 (en) 2001-06-27
WO2002090346A1 (en) 2002-11-14
US20110130399A1 (en) 2011-06-02
EP1387836A1 (de) 2004-02-11
ES2301648T3 (es) 2008-07-01
US7399761B2 (en) 2008-07-15
JP2004532241A (ja) 2004-10-21
DE60226225D1 (de) 2008-06-05
PT1387836E (pt) 2008-06-27
BR0209332A (pt) 2004-07-20
EP1387836B1 (de) 2008-04-23
DE60226225T2 (de) 2009-09-10
US20090076003A1 (en) 2009-03-19
CN1507444A (zh) 2004-06-23
US20040180899A1 (en) 2004-09-16
JP4365586B2 (ja) 2009-11-18
CN1314681C (zh) 2007-05-09
CA2446051A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
RU93004484A (ru) Производные пиразола, способ их получения и содержащие их фармацевтические композиции
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
PL361341A1 (pl) Nowa kompozycja farmaceutyczna
WO2004071400A3 (en) Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
TR199900674T2 (xx) Kinazolin t�revleri ve bunlar� i�eren farmas�tik bile�imler.
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
EP4442321A3 (de) Methoden zur behandlung von sjögren-syndrom mit einem hemmer von bruton-kinase
CY1108004T1 (el) Χρηση r-αρυλοπροπιονικων οξεων για την παραγωγη φαρμακων για την αντιμετωπιση παθησεων σε ανθρωπους και ζωα, οι οποιες μπορουν να επηρεαστουν θepαπευτικα μεσω της αναστολης της ενepγοποιησης του nf-kb
ATE393152T1 (de) Phtalazine derivate mit angiogenesis inhibierender wirkung
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
SE0102440D0 (sv) New compound
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
ATE289805T1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
SE0002729D0 (sv) Novel compound form
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1387836

Country of ref document: EP